New research reveals concerning drops in RSV vaccine effectiveness among older adults, raising critical questions about the long-term protection promised by pharmaceutical giants and federal health agencies.
Story Highlights
- RSV vaccines showed strong initial protection of 77-83% effectiveness in preventing hospitalizations
- Real-world data confirms clinical trial results but raises questions about duration of protection
- Low vaccine uptake among older adults despite CDC recommendations
- Ongoing monitoring needed to determine if booster shots will be required
Initial Promise Shows Strong Protection Rates
RSV vaccines approved by the FDA in 2023 demonstrated impressive initial effectiveness rates during their first season of widespread use. GSK’s Arexvy vaccine showed 77-83% effectiveness in preventing RSV-related hospitalizations and emergency visits among adults aged 60 and older. Pfizer’s Abrysvo vaccine performed similarly with 73-79% effectiveness rates. These results validated decades of research following the catastrophic failure of early RSV vaccines in the 1960s that actually worsened disease outcomes in children.
The vaccines maintained consistent effectiveness across different age groups, including those 75 and older and immunocompromised individuals. Multiple real-world studies confirmed the clinical trial data, providing reassurance that the vaccines perform as advertised in diverse populations. Healthcare systems reported significant reductions in RSV-related ICU admissions and deaths among vaccinated older adults during the 2023-2024 respiratory season.
Duration Questions Emerge From Limited Data
While initial effectiveness appears strong, researchers acknowledge significant gaps in understanding long-term protection. No evidence of waning protection emerged within the first RSV season, but this limited timeframe prevents definitive conclusions about durability. Some clinical trial data suggests protection may last 18-23 months, but real-world data beyond the first season remains unavailable. This uncertainty mirrors concerns conservatives have raised about rushed vaccine timelines and incomplete long-term safety data.
Experts urge caution regarding the duration of protection and potential need for booster doses. Some studies focused primarily on veteran populations, raising questions about generalizability to the broader American public. The CDC continues monitoring vaccine effectiveness while maintaining recommendations for adults 60 and older, but acknowledges that ongoing surveillance is essential for detecting waning immunity and rare adverse events.
Low Uptake Rates Concern Health Officials
Despite strong initial effectiveness data, RSV vaccine uptake remains disappointingly low among the target population. Researchers consistently highlight the need for increased vaccination coverage to achieve meaningful public health impact. This pattern reflects broader vaccine hesitancy concerns, particularly among older Americans who have grown skeptical of government health recommendations following COVID-19 policy failures and constantly changing guidance from federal agencies.
💉 𝗥𝗦𝗩 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝗗𝗿𝗼𝗽𝘀 𝗔𝗺𝗼𝗻𝗴 𝗢𝗹𝗱𝗲𝗿 𝗔𝗱𝘂𝗹𝘁𝘀: 𝗦𝘁𝘂𝗱𝘆
Read more:https://t.co/2sCcPvd2bU pic.twitter.com/KfHONis3TO
— The Epoch Times (@EpochTimes) August 27, 2025
Healthcare providers face challenges convincing eligible patients to receive RSV vaccines, especially when questions about protection duration remain unanswered. The pharmaceutical companies behind these vaccines continue promoting their products while collecting substantial revenues from government purchases and insurance reimbursements. Long-term care facilities report lower outbreak risks among vaccinated residents, but overall population-level protection depends on achieving higher vaccination rates than currently observed.
Sources:
RSV Vaccine Clinical Guidance for Adults
RSV vaccines effective but more people need to get them
Real-world study: RSV vaccine 78%-80% effective against infection
